| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1832* | 2021 |
| Consensus statement for inert gas washout measurement using multiple-and single-breath tests PD Robinson, P Latzin, S Verbanck, GL Hall, A Horsley, M Gappa, ... European Respiratory Journal 41 (3), 507-522, 2013 | 780 | 2013 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 757 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 611* | 2021 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 465 | 2021 |
| Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial PD Monk, RJ Marsden, VJ Tear, J Brookes, TN Batten, M Mankowski, ... The Lancet Respiratory Medicine 9 (2), 196-206, 2021 | 460 | 2021 |
| Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection J Zuo, AC Dowell, H Pearce, K Verma, HM Long, J Begum, F Aiano, ... Nature immunology 22 (5), 620-626, 2021 | 413 | 2021 |
| VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles JC Davies, SM Moskowitz, C Brown, A Horsley, MA Mall, EF McKone, ... New england journal of medicine 379 (17), 1599-1611, 2018 | 340 | 2018 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 283 | 2022 |
| Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis AR Horsley, PM Gustafsson, KA Macleod, C Saunders, AP Greening, ... Thorax 63 (2), 135-140, 2008 | 279 | 2008 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 231 | 2022 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 215 | 2022 |
| Lung clearance index in the assessment of airways disease A Horsley Respiratory medicine 103 (6), 793-799, 2009 | 199 | 2009 |
| Efficacy and complications of small-bore, wire-guided chest drains A Horsley, L Jones, J White, M Henry Chest 130 (6), 1857-1863, 2006 | 164 | 2006 |
| Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation AR Horsley, JC Davies, RD Gray, KA Macleod, J Donovan, ZA Aziz, ... Thorax 68 (6), 532-539, 2013 | 152 | 2013 |
| Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease KA Macleod, AR Horsley, NJ Bell, AP Greening, JA Innes, S Cunningham Thorax 64 (1), 33-37, 2009 | 142 | 2009 |
| Preschool multiple-breath washout testing. An official American Thoracic Society technical statement PD Robinson, P Latzin, KA Ramsey, S Stanojevic, P Aurora, SD Davis, ... American journal of respiratory and critical care medicine 197 (5), e1-e19, 2018 | 105 | 2018 |
| Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease PJ Barry, BJ Plant, A Nair, S Bicknell, NJ Simmonds, NJ Bell, NT Shafi, ... Chest 146 (1), 152-158, 2014 | 95 | 2014 |
| Detection of early subclinical lung disease in children with cystic fibrosis by lung ventilation imaging with hyperpolarised gas MRI H Marshall, A Horsley, CJ Taylor, L Smith, D Hughes, FC Horn, AJ Swift, ... Thorax 72 (8), 760-762, 2017 | 91 | 2017 |
| Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers RJ Harris, HJ Whitaker, NJ Andrews, F Aiano, Z Amin-Chowdhury, J Flood, ... Journal of Infection 82 (5), 162-169, 2021 | 84 | 2021 |
